Genentech ( Genentech )


Genentech's picture

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.

Genentech press release, blog etc

06/13/2018 - 12:03 FDA Approves Genentechs Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
06/13/2018 - 11:06 Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
06/08/2018 - 11:19 Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
06/07/2018 - 08:36 FDA Approves Genentechs Rituxan (Rituximab) for Pemphigus Vulgaris
06/04/2018 - 05:29 FDA Grants Priority Review to Genentechs HEMLIBRA (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors
06/02/2018 - 12:17 Phase III IMpower131 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer
05/28/2018 - 07:32 Phase III IMpower130 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
05/16/2018 - 15:22 Follow-Up Phase III Data Showed Genentechs Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death
05/14/2018 - 13:08 FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis
05/12/2018 - 20:52 Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress
05/08/2018 - 22:47 Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
05/05/2018 - 23:51 FDA Grants Priority Review to Genentechs Cancer Immunotherapy Tecentriq (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
04/21/2018 - 21:37 New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
04/16/2018 - 00:54 FDA Grants Breakthrough Therapy Designation For Genentechs HEMLIBRA (emicizumab-kxwh) in Hemophilia A Without Inhibitors
04/15/2018 - 00:14 Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
03/24/2018 - 23:32 Phase III IMpower150 Study Showed Genentechs TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Carboplatin and Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared to Avastin Plus Carboplatin and Paclitaxel
03/21/2018 - 13:38 FDA Approves Genentechs Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
02/13/2018 - 01:40 FDA Grants Priority Review for Genentechs Rituxan (Rituximab) for Pemphigus Vulgaris